– Achieved 4Q revenue of KRW 88.9bn, operating profit of KRW 36.8bn, net profit of KRW 17.1bn, respectively 4%, 22.4%, 451.6% YoY growth – FY 23 Sales growth of 5.2% and 25.1% for botulinum toxin and HA filler, with growth in domestic and international markets SEOUL, South Korea, Feb. 14,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.